Literature DB >> 29442040

Lidocaine sensitizes the cytotoxicity of 5-fluorouacil in melanoma cells via upregulation of microRNA-493.

Yingbin Wang, Jianqin Xie, Wei Liu, Rongzhi Zhang, Shenghui Huang, Yanhong Xing.   

Abstract

Lidocaine is a well-documented local anesthetic that has been reported to sensitize the cytotoxicity of cisplatin in cancer cells. However, little information is available concerning whether lidocaine sensitizes the cytotoxicity of 5-fluorouracil (5-FU) in melanoma cells. The study was aimed to explore the effects and mechanisms of lidocaine on the sensitivity to 5-FU in the melanoma cell line SK-MEL-2. Cell viability and apoptosis were analyzed after administration of different concentrations of lidocaine, 5-FU, or the combinations. Expression of microRNA (miR)-493 was assessed following lidocaine administration. The target genes of miR-493 were verified by luciferase reporter assay, PCR, and Western blot. The effects of abnormal expression of miR-493 and/or SRY-Box 4 (SOX4) on cell viability, apoptosis, and key proteins in phosphatidylinositol-3-kinase (PI3K)/AKT and the Smad pathways were detected. The effects of (0-100 uM) lidocaine on cell viability and apoptosis was not obvious; however, lidocaine could significantly increase the cell viability and inhibit apoptosis in 5-FU-treated cells. In addition, lidocaine induced upregulation of miR-493 in a dose-dependent manner, and we confirmed that the effects of miR-493 on the sensitivity were by upregulating miR-493. Moreover, we verified that Sox4 was a target of miR-493, and Sox4 overexpression decreased the sensitivity to 5-FU. Besides, Sox4 overexpression increased the levels of p-PI3K, p-AKT, p-Smad2 and p-Smad3, and Sox4 suppression showed contrary results. Our results suggest that lidocaine sensitizes the cytotoxicity of 5-FU in melanoma cells via upregulation of miR-493, which might be involved in SOX4-mediated PI3K/AKT and Smad pathways.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29442040     DOI: 10.1691/ph.2017.7616

Source DB:  PubMed          Journal:  Pharmazie        ISSN: 0031-7144            Impact factor:   1.267


  6 in total

1.  Lidocaine enhances the efficacy of palbociclib in triple-negative breast cancer.

Authors:  Beom Seok Han; Kyung Hee Jung; Ji Eun Lee; Young-Chan Yoon; Soyeon Ko; Min Seok Park; Yun Ji Lee; Sang Eun Kim; Ye Jin Cho; Pureunchowon Lee; Joo Han Lim; Eunsoo Jang; Hyunzu Kim; Soon-Sun Hong
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

Review 2.  The Use of Intravenous Lidocaine in Perioperative Medicine: Anaesthetic, Analgesic and Immune-Modulatory Aspects.

Authors:  Ingrid Wing-Sum Lee; Stefan Schraag
Journal:  J Clin Med       Date:  2022-06-20       Impact factor: 4.964

3.  Lidocaine has antitumor effect on hepatocellular carcinoma via the circ_DYNC1H1/miR-520a-3p/USP14 axis.

Authors:  Hua Liu; Jing Cheng; Heng Xu; Zhenzhen Wan
Journal:  Open Life Sci       Date:  2021-08-09       Impact factor: 0.938

4.  Lidocaine represses proliferation and cisplatin resistance in cutaneous squamous cell carcinoma via miR-30c/SIRT1 regulation.

Authors:  Tao Liu; Fei Jiang; Li-Yuan Yu; You-Yang Wu
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

Review 5.  Impact of local anesthetics on epigenetics in cancer.

Authors:  Lucillia Bezu; Oliver Kepp; Guido Kroemer
Journal:  Front Oncol       Date:  2022-08-30       Impact factor: 5.738

Review 6.  Anesthesia Options and the Recurrence of Cancer: What We Know so Far?

Authors:  Juan P Cata; Carlos Guerra; German Soto; Maria F Ramirez
Journal:  Local Reg Anesth       Date:  2020-07-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.